Gilead Third Quarter Earnings

By Investopedia Staff | October 23, 2012 AAA

Gilead (Nasdaq:GILD) announced its results for the most recent quarter on October 23, 2012. Gilead Sciences is a biopharmaceutical company which discovers, develops and commercializes therapies for viral diseases, infectious diseases and cancer.

In most situations, when earnings do not meet analyst estimates, a business' stock price will tend to drop. On the other hand, when actual earnings beat estimates by a significant amount, the share price will likely surge. SEE: 12 Things You Need To Know About Financial Statements

The Numbers: Gilead's latest numbers were good, as the company announced EPS and revenues that came in ahead predictions. The company reported adjusted net income of $1 per share versus the 92 cents per share estimate and revenues of $2.43 billion versus the $2.29 billion estimate. Revenue climbed 14.4% from the same period last year. Gilead's revenue has grown during each of the past four quarters on a year-over-year basis. The company's net income for the quarter was $675.5 million. This is a 8.9% decline from last year. Last quarter marks the third in a row in which the company's net income has fallen. Profits declined 4.6% in the second quarter and 32.1% in the first quarter.

A Look Back: Margins rose in the second quarter after falling the quarter before. Gross margin grew 0.5 percentage point from the year-earlier quarter to 75.4%. In the first quarter, the figure rose 0.7 percentage point to 74.3% from the year earlier quarter.

Looking Ahead: Analysts appear increasingly negative about the company's results for the next quarter. The average estimate for the fourth quarter has moved down from 91 cents a share to 90 cents over the last 30 days. Decreasing earnings estimates is generally a negative sign as it suggests analyst believe future earnings to be weaker than previously anticipated. The average estimate for the fiscal year is $3.44 per share, down from $3.67 90 days ago.

comments powered by Disqus
Related Analysis
  1. Q2 Earnings Season in Rearview Mirror - Earnings Trends
    Stock Analysis

    Q2 Earnings Season in Rearview Mirror - Earnings Trends

  2. Shocking Prediction #9: 'Nightmare Pandemics' Could Make These 5 Stocks Soar
    Investing

    Shocking Prediction #9: 'Nightmare Pandemics' Could Make These 5 Stocks Soar

  3. Unconventional Drilling Still Has Room To Boom
    Stock Analysis

    Unconventional Drilling Still Has Room To Boom

  4. Finding An Alternative With Currency ETFs
    Stock Analysis

    Finding An Alternative With Currency ETFs

  5. Record Earnings & Stronger Growth in Q2 - Earnings Trends
    Stock Analysis

    Record Earnings & Stronger Growth in Q2 - Earnings Trends

Trading Center